Cancer
Malignant Lung Neoplasm
CI-CAN-00001140Explore in graph →
Top-level2,648 active trials51 approved drugs619 evidence items
- NCIt
- C7377
- ICD-10
- C33-C34
- DOID
- 1324
- Other
- 1 more code
Loading cancer entity…
Loading cancer entity…
Cancer
CI-CAN-00001140Explore in graph →
Clinical trials
11,122 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,489)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01242072 | Intravenous Palifosfamide-tris in Combination With Etoposide and Carboplatin in Patients With Malignancies | completed | Phase 1 | 22 | Alaunos TherapeuticsINDUSTRY | 1 | Sep 29, 2026 | clinicaltrials |
| NCT05642195 | Evaluation of a Cancer Lysate Vaccine and Montanide (Registered Trademark) ISA-51 VG With or Without the IL-15 Super-Agonist N-803 as Adjuvant Therapy for PD-L1 Negative Non-Small Cell Lung Cancer | suspended | Phase 1 / Phase 2 | 30 | National Cancer Institute (NCI)NIH | 1 | Sep 29, 2026 |
| clinicaltrials |
| NCT05845671 | Amivantamab With Tyrosine Kinase Inhibitors (TKI) for Advanced NSCLC With ALK, ROS1, or RET Alterations | active not recruiting | Phase 1 / Phase 2 | 12 | University of Colorado, DenverOTHER | 1 | Sep 29, 2026 | clinicaltrials |
| NCT05877599 | A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation | recruiting | Phase 1 | 45 | AstraZenecaINDUSTRY | 1 | Sep 29, 2026 | clinicaltrials |
| NCT05891171 | Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced Cancers(ARC-25) | active not recruiting | Phase 1 | 40 | Arcus Biosciences, Inc.INDUSTRY | 3 | Sep 29, 2026 | clinicaltrials |
| NCT06479811 | [212Pb]VMT-Alpha-NET in Metastatic or Inoperable Somatostatin-Receptor Positive Gastrointestinal Neuroendocrine Tumors, Pheochromocytoma/Paragangliomas, Small Cell Lung, Renal Cell, and Head and Neck Cancers | recruiting | Phase 1 | 120 | National Cancer Institute (NCI)NIH | 1 | Sep 29, 2026 | clinicaltrials |
| NCT06694454 | Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC) | suspended | Phase 1 / Phase 2 | 60 | National Cancer Institute (NCI)NIH | 1 | Sep 29, 2026 | clinicaltrials |
| NCT07127874 | A Study of PHN-012 in Patients With Advanced Solid Tumors | recruiting | Phase 1 | 165 | Pheon TherapeuticsINDUSTRY | 3 | Sep 29, 2026 | clinicaltrials |
| NCT07140315 | DK222 Study at Hopkins | recruiting | Phase 1 | 6 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Sep 29, 2026 | clinicaltrials |
| NCT07509034 | Autologous B7-H3 Chimeric Antigen Receptor T Cells in Previously Treated Extensive-Stage Small Cell Lung Cancer With Recurrent or Refractory Disease | recruiting | Phase 1 | 40 | National Cancer Institute (NCI)NIH | 1 | Sep 29, 2026 | clinicaltrials |
| NCT07578571 | A Phase 1 Study of IM-1617 in Participants With Advanced Cancer | recruiting | Phase 1 | 175 | Immunome, Inc.INDUSTRY | 1 | Sep 29, 2026 | clinicaltrials |
| NCT07705035 | DBC-664 in Adult Patients With Solid Tumors | recruiting | Phase 1 | 210 | Duboce Biopharmaceuticals, Inc.INDUSTRY | 1 | Sep 29, 2026 | clinicaltrials |
| NCT07707895 | DAREON®-36: A Study to Test Obrixtamig in Combination With ZL-1310 in People With Advanced Small Cell Lung Cancer or Other Neuroendocrine Cancers | not yet recruiting | Phase 1 / Phase 2 | 60 | Boehringer IngelheimINDUSTRY | 11 | Sep 29, 2026 | clinicaltrials |
| NCT07830342 | A Clinical Study of HS-IT101 Injection in Patients With Advanced Non-Small Cell Lung Cancer | recruiting | Phase 1 | 24 | Hangzhou Huasai Biomedicine Co., Ltd.INDUSTRY | 1 | Sep 29, 2026 | clinicaltrials |
| NCT07846358 | This is a Multicenter, Open-label, Phase I/II Study to Explore the Safety, Tolerability, Pharmacokinetics (PK), and Preliminary Efficacy of GFH276 in Patients With Advanced NSCLC Harboring a RAS Mutation.(GFH276X1203) | not yet recruiting | Phase 1 / Phase 2 | 84 | Genfleet Therapeutics (Shanghai) Inc.INDUSTRY | 0 | Sep 29, 2026 | clinicaltrials |
| NCT05753722 | A First-in-human Study of PRTH-101 Monotherapy +/- Pembrolizumab in Subjects With Advanced Malignancies | completed | Phase 1 | 79 | Incendia TherapeuticsINDUSTRY | 1 | Sep 28, 2026 | clinicaltrials |
| NCT06586957 | A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors | recruiting | Phase 1 | 238 | NiKang Therapeutics, Inc.INDUSTRY | 1 | Sep 28, 2026 | clinicaltrials |
| NCT07843940 | A Study to Test Obrixtamig in Combination With Pumitamig in People With Advanced Small Cell Lung Cancer (Dareon®-Rosetta35) | not yet recruiting | Phase 1 / Phase 2 | 55 | Boehringer IngelheimINDUSTRY | 10 | Sep 28, 2026 | clinicaltrials |
| NCT02595931 | M6620 and Irinotecan Hydrochloride in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery | active not recruiting | Phase 1 | 66 | National Cancer Institute (NCI)NIH | 1 | Sep 25, 2026 | clinicaltrials |
| NCT02609776 | Study of Amivantamab, a Human Bispecific EGFR and cMet Antibody, in Participants With Advanced Non-Small Cell Lung Cancer(CHRYSALIS) | active not recruiting | Phase 1 | 751 | Janssen Research & Development, LLCINDUSTRY | 10 | Sep 25, 2026 | clinicaltrials |
| NCT03460977 | A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma | recruiting | Phase 1 | 453 | PfizerINDUSTRY | 8 | Sep 25, 2026 | clinicaltrials |
| NCT03568656 | Study to Evaluate CCS1477 in Advanced Tumours | completed | Phase 1 / Phase 2 | 219 | CellCentric Ltd.INDUSTRY | 6 | Sep 25, 2026 | clinicaltrials |
| NCT05488314 | A Study of Amivantamab and Capmatinib Combination Therapy in Unresectable Metastatic Non-small Cell Lung Cancer(METalmark) | active not recruiting | Phase 1 / Phase 2 | 57 | Janssen Research & Development, LLCINDUSTRY | 13 | Sep 25, 2026 | clinicaltrials |
| NCT05647122 | First in Human Study of AZD9592 in Solid Tumors(EGRET) | active not recruiting | Phase 1 | 190 | AstraZenecaINDUSTRY | 11 | Sep 25, 2026 | clinicaltrials |
| NCT05908734 | A Study of Combination Therapy With Amivantamab and Cetrelimab in Participants With Metastatic Non-small Cell Lung Cancer(PolyDamas) | active not recruiting | Phase 1 / Phase 2 | 71 | Janssen Research & Development, LLCINDUSTRY | 9 | Sep 25, 2026 | clinicaltrials |
| NCT06116786 | A Study of JNJ-86974680 in Participants With Advanced Non-small Cell Lung Cancer | active not recruiting | Phase 1 | 67 | Johnson & Johnson Enterprise Innovation Inc.INDUSTRY | 4 | Sep 25, 2026 | clinicaltrials |
| NCT06218914 | Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors | recruiting | Phase 1 | 108 | AstraZenecaINDUSTRY | 1 | Sep 25, 2026 | clinicaltrials |
| NCT06579196 | Trabedersen (OT-101) With Pembrolizumab for Newly Diagnosed Advanced NSCLC and Positive PD-L1 | active not recruiting | Phase 1 / Phase 2 | 45 | University of NebraskaOTHER | 1 | Sep 25, 2026 | clinicaltrials |
| NCT07037758 | A Study of Tarlatamab in Combination With AB248 in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-311)(DeLLphi-311) | recruiting | Phase 1 | 380 | AmgenINDUSTRY | 3 | Sep 25, 2026 | clinicaltrials |
| NCT07227025 | A Study of Amivantamab and Olomorasib Combination Therapy in Participants With Metastatic Non-Small Cell Lung Cancer(KaRAnaSa) | recruiting | Phase 1 / Phase 2 | 60 | Janssen Research & Development, LLCINDUSTRY | 5 | Sep 25, 2026 | clinicaltrials |
| NCT07227298 | Symbiotic-Lung-20: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers | recruiting | Phase 1 / Phase 2 | 162 | PfizerINDUSTRY | 9 | Sep 25, 2026 | clinicaltrials |
| NCT07579221 | Ph1/2 Trial Of Navlimetostat With Pumitamig In MTAP-Deficient Advanced Non-Small Cell Lung Cancer | recruiting | Phase 1 / Phase 2 | 17 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 25, 2026 | clinicaltrials |
| NCT07663630 | A Study to Learn About the Study Medicine Called Ponsegromab in Adults With Lung Cancer-Associated Significant Body Weight Loss | not yet recruiting | Phase 1 | 80 | PfizerINDUSTRY | 2 | Sep 25, 2026 | clinicaltrials |
| NCT07670312 | Evaluation of XYA02 in Patients With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 190 | XYone Therapeutics, IncINDUSTRY | 1 | Sep 25, 2026 | clinicaltrials |
| NCT04844073 | A Study of TAK-186 (Also Known as MVC-101) in Adults With Advanced or Metastatic Cancer | terminated | Phase 1 / Phase 2 | 95 | TakedaINDUSTRY | 4 | Sep 24, 2026 | clinicaltrials |
| NCT06047379 | Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis | recruiting | Phase 1 / Phase 2 | 134 | Neonc Technologies, Inc.INDUSTRY | 1 | Sep 24, 2026 | clinicaltrials |
| NCT06447662 | A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation. | active not recruiting | Phase 1 | 64 | PfizerINDUSTRY | 2 | Sep 24, 2026 | clinicaltrials |
| NCT06799286 | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of BMS-986489 in Chinese Participants With Relapsed/Refractory Small Cell Lung Cancer | completed | Phase 1 | 10 | Bristol-Myers SquibbINDUSTRY | 1 | Sep 24, 2026 | clinicaltrials |
| NCT07559929 | A Study of DXC006 With Immune Checkpoint Inhibitors or Platinum for Small Cell Lung Cancer. | recruiting | Phase 1 / Phase 2 | 200 | Hangzhou DAC Biotechnology Co., Ltd.INDUSTRY | 1 | Sep 24, 2026 | clinicaltrials |
| NCT03381274 | Oleclumab (MEDI9447) Epidermal Growth Factor Receptor Mutant (EGFRm) Non-small Cell Lung Cancer (NSCLC) Novel Combination Study | active not recruiting | Phase 1 / Phase 2 | 43 | MedImmune LLCINDUSTRY | 3 | Sep 23, 2026 | clinicaltrials |
| NCT04044859 | ADP-A2M4CD8 as Monotherapy or in Combination With Either Nivolumab or Pembrolizumab in HLA-A2+ Subjects With MAGE-A4 Positive Tumors (SURPASS) | active not recruiting | Phase 1 | 120 | USWM CT, LLCINDUSTRY | 3 | Sep 23, 2026 | clinicaltrials |
| NCT06253520 | Autologous T-cells Genetically Engineered to Express Receptors Reactive Against KRAS Mutations in Conjunction With a Vaccine Directed Against These Antigens in Participants With Metastatic Cancer | active not recruiting | Phase 1 | 210 | National Cancer Institute (NCI)NIH | 1 | Sep 23, 2026 | clinicaltrials |
| NCT06618287 | A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 416 | Bristol-Myers SquibbINDUSTRY | 10 | Sep 23, 2026 | clinicaltrials |
| NCT07140016 | A Study of Gilteritinib in Adults With Advanced ALK-positive Non-small Cell Lung Cancer (NSCLC) | recruiting | Phase 1 | 40 | Astellas Pharma Global Development, Inc.INDUSTRY | 3 | Sep 23, 2026 | clinicaltrials |
| NCT07177937 | A Study of DXC014 in Patients With Advanced Solid Tumors. | recruiting | Phase 1 | 150 | Hangzhou DAC Biotechnology Co., Ltd.INDUSTRY | 1 | Sep 23, 2026 | clinicaltrials |
| NCT07339176 | Intratumoral N17350 in Advanced Solid Tumors(OP-NEU-101) | recruiting | Phase 1 / Phase 2 | 275 | Onchilles Pharma IncINDUSTRY | 2 | Sep 23, 2026 | clinicaltrials |
| NCT05745740 | A Study of RC48-ADC Combined With Pyrotinib For Treatment of Local Advanced or Metastasis NSCLC With HER2 Mutation | not yet recruiting | Phase 1 / Phase 2 | 26 | RemeGen Co., Ltd.INDUSTRY | 1 | Sep 22, 2026 | clinicaltrials |
| NCT06066138 | A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing | recruiting | Phase 1 | 30 | National Cancer Institute (NCI)NIH | 1 | Sep 22, 2026 | clinicaltrials |
| NCT06128551 | Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors | recruiting | Phase 1 / Phase 2 | 534 | Revolution Medicines, Inc.INDUSTRY | 7 | Sep 22, 2026 | clinicaltrials |
Data updated 6 hours agoSource updated Sep 29, 2026source: clinicaltrials